# Esophageal Neoplasms trials: 221 new since Nov 2024

Updated October 29, 2026.

221 clinical studies in Esophageal Neoplasms were first posted on ClinicalTrials.gov from November 12, 2024 to October 29, 2026; 40 have an industry sponsor and 183 are recruiting or about to. The newest, NCT07904260, was posted on October 29, 2026: Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal... (Diansan Su).

## The full list

New Esophageal Neoplasms clinical trials: 221 rows for $11.05, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/esophageal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 221
- Industry sponsored: 40
- Recruiting or not yet: 183
- Latest posted: October 29, 2026

## Newest trials

The newest 100 of 221, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 29, 2026 | NCT07904260 | Effect of High-flow Nasal Cannula Oxygenation on the Incidence of Hypoxemia During Painless Gastrointestinal Endoscopy in Patients at High... | Diansan Su | Not applicable | Not yet recruiting | Hypoxemia, Gastric Cancer (Diagnosis), Esophageal Cancer, High-altitude Illness, Obstructive Sleep Apnea (OSA) | 430 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904260) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 29, 2026 | NCT07902544 | Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell Carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Observational | Completed | Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Metastasis | 717 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902544) |
| October 22, 2026 | NCT07890038 | The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Active not recruiting | Nasopharyngeal Cancers, Lung Cancer (NSCLC), Esophageal Cancer, Glioma | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890038) |
| October 22, 2026 | NCT07888140 | Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer | Ruijin Hospital | Phase 3 | Recruiting | Esophageal Cancer | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888140) |
| October 7, 2026 | NCT07863141 | A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC... | Sun Yat-sen University | Phase 2 | Recruiting | Esophageal Cancer (EC) | 112 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863141) |
| September 22, 2026 | NCT07834268 | Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS) | Fifth Affiliated Hospital of Guangzhou Medical University | Not applicable | Active not recruiting | Colorectal Cancer, Grastic Cancer, Esophageal Cancer, Lung Cancer, Liver Cancer | 1,250 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07834268) |
| September 18, 2026 | NCT07828314 | Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study | Portsmouth Hospitals NHS Trust | Observational | Completed | Oesophageal Cancer | 118 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828314) |
| September 16, 2026 | NCT07822399 | A Study of MGC030 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer | 314 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822399) |
| September 14, 2026 | NCT07818018 | A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma | Memorial Sloan Kettering Cancer Center | Phase 1/2 | Recruiting | Esophageal Cancer, Advanced Esophageal Cancer, Gastric Cancer, Advanced Gastric Cancer, Gastroesophageal Junction... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818018) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| September 10, 2026 | NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | SK Life Science, Inc. | Phase 1 | Recruiting | Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer... | 100 | South Korea, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812805) |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| September 8, 2026 | NCT07806500 | Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors | Beijing Anjianxi Bio-Medical Technology Co., Ltd. | Phase 1 | Not yet recruiting | Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806500) |
| August 31, 2026 | NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | University of California, Irvine | Phase 2 | Recruiting | Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel... | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795749) |
| August 28, 2026 | NCT07791979 | High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease | Zhejiang University | Not applicable | Not yet recruiting | Hypoxemia, Gastric Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Esophageal Cancer | 90 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791979) |
| August 26, 2026 | NCT07788001 | A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal... | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG), Disease Free Survival | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788001) |
| August 24, 2026 | NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | Lumina Pharmaceuticals Inc | Early phase 1 | Not yet recruiting | Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC)... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781852) |
| August 24, 2026 | NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA | Jazz Pharmaceuticals | Observational | Not yet recruiting | Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer, Stomach... | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780968) |
| August 21, 2026 | NCT07780721 | Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer | The Affiliated Hospital of Putian University | Phase 2 | Not yet recruiting | Esophageal Cancer | 31 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780721) |
| August 21, 2026 | NCT07778056 | Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study | Henan Cancer Hospital | Observational | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778056) |
| August 20, 2026 | NCT07775859 | NOMAD-GI: Molecular-guided Non-operative Management and Organ Preservation Strategy After Precision Therapy in Gastrointestinal Cancers | Peking University Cancer Hospital & Institute | Observational | Not yet recruiting | Gastrointestinal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Colorectal Cancer | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775859) |
| August 18, 2026 | NCT07770672 | An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell... | Tan Lijie | Phase 2 | Not yet recruiting | Esophageal Cancer, ESCC | 92 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770672) |
| August 18, 2026 | NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | Mark Bernard | Phase 2 | Recruiting | Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC) | 35 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770100) |
| August 11, 2026 | NCT07757022 | AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer | Henan Cancer Hospital | Observational | Not yet recruiting | Esophageal Cancer | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757022) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07745322 | Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer | Peking University Cancer Hospital & Institute | Observational | Active not recruiting | Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms | 270 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745322) |
| July 29, 2026 | NCT07733830 | Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Esophageal Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733830) |
| July 20, 2026 | NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection | Imperial College London | Observational | Recruiting | Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal... | 1,000 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714538) |
| July 14, 2026 | NCT07702253 | O-GlcNAcylation Induced HMGB1 Signalling | Chinese University of Hong Kong | Observational | Active not recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 120 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702253) |
| July 14, 2026 | NCT07700420 | Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer | University of Texas Southwestern Medical Center | Phase 1 | Recruiting | Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700420) |
| July 9, 2026 | NCT07692204 | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer | Sanofi | Phase 2 | Recruiting | Gastric Cancer, Oesophageal Carcinoma | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692204) |
| July 9, 2026 | NCT07691944 | Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients | First Affiliated Hospital of Chongqing Medical University | Observational | Not yet recruiting | Esophageal Cancer (EsC), Postoperative Pulmonary Complications (PPCs) | 126 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691944) |
| July 6, 2026 | NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor... | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685938) |
| June 26, 2026 | NCT07671625 | Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally... | Masaryk Memorial Cancer Institute | Not applicable | Recruiting | Locally Advanced Esophageal Cancer, Gastroesophageal Junction Cancer, Gastric Cancer | 60 | Czechia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671625) |
| June 18, 2026 | NCT07658313 | Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery | Ludwig Boltzmann Institute for Digital Health and Prevention | Not applicable | Not yet recruiting | Gastrointestinal Neoplasms, Pancreatic Neoplasms, Liver Neoplasm, Oesophageal Cancer, Gastrointestinal Cancer... | 30 | Austria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658313) |
| June 11, 2026 | NCT07642492 | REcovery After Cancer Application | Karolinska Institutet | Not applicable | Not yet recruiting | Oesophageal Cancer, Gastric Cancer (Diagnosis) | 250 | Sweden | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642492) |
| June 11, 2026 | NCT07642401 | Large-scale Models of Esophageal Cancer and Related Research | The First Affiliated Hospital of Henan University of Science and Technology | Observational | Enrolling by invitation | Esophageal Cancer | 12,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642401) |
| June 10, 2026 | NCT07638410 | Prehabilitation in High-risk Oncologic Surgery | Fox Chase Cancer Center | Not applicable | Recruiting | Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer, Bladder Cancer, Ovarian Cancer, Abdominal... | 180 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638410) |
| June 5, 2026 | NCT07629921 | Multimodal Al for Precision Diagnosis of Esophageal Cancer | Shanghai Zhongshan Hospital | Observational | Terminated | Esophageal Cancer | 264 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629921) |
| June 4, 2026 | NCT07625930 | RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 | Not yet recruiting | Gastroesophageal Adenocarcinoma | 184 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625930) |
| June 1, 2026 | NCT07617246 | The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Esophagus Cancer, Lung Cancer | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617246) |
| May 22, 2026 | NCT07605312 | AI-Based Risk Prediction Model for Upper Digestive Tract Cancer | National Taiwan University Hospital | Observational | Not yet recruiting | Gastric Cancer (GC), Premalignant Lesion, Gastric Intestinal Metaplasia, Atrophic Gastritis, Dysplasia Stomach... | 10,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605312) |
| May 22, 2026 | NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma | Duke University | Phase 2 | Recruiting | Esophageal Adenocarcinoma | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603375) |
| May 19, 2026 | NCT07596732 | Statewide Unified Network for Remote Intervention of Strength and Exercise | AdventHealth Translational Research Institute | Not applicable | Not yet recruiting | Gastric Cancer (Diagnosis), Esophagus Cancer, Pancreas Cancer, Colon Cancer, Rectal Cancer, Lung Cancer | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596732) |
| May 19, 2026 | NCT07596654 | The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer | yi shen | Observational | Recruiting | Esophageal Carcinoma, Limited-Stage Small Cell Esophageal Carcinoma | 4 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596654) |
| May 19, 2026 | NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | Northwestern University | Phase 1/2 | Recruiting | Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant... | 72 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594626) |
| May 13, 2026 | NCT07584577 | Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in... | University Hospital, Bordeaux | Observational | Recruiting | Esophageal Cancer, Surgery Indication, Malnourished, Neoadjuvant Treatment | 670 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584577) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| May 11, 2026 | NCT07578571 | A Phase 1 Study of IM-1617 in Participants With Advanced Cancer | Immunome, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578571) |
| May 7, 2026 | NCT07573397 | A Prospective Study of Tumor-specific Tpex in Negative Lymph Nodes for Predicting Pathological Complete Response to Neoadjuvant PD 1... | Fudan University | Observational | Not yet recruiting | Esophageal Cancer | 88 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573397) |
| May 4, 2026 | NCT07565857 | Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer | Natera, Inc. | Not applicable | Not yet recruiting | Gastric-Esophageal Cancer | 1,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565857) |
| May 1, 2026 | NCT07561840 | Exercise Training After Upper Gastrointestinal Cancer Surgery | Kansai Medical University | Not applicable | Recruiting | Esophageal Cancer, Gastric Cancer (Diagnosis), Upper Gastrointestinal Cancer | 171 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561840) |
| April 24, 2026 | NCT07549269 | Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A... | Sichuan University | Observational | Completed | Esophageal Cancer | 387 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549269) |
| April 16, 2026 | NCT07533357 | Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced or Recurrent Esophageal... | Fudan University | Observational | Not yet recruiting | Esophageal Cancer | 158 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533357) |
| April 15, 2026 | NCT07530549 | A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Local Advanced Esophageal Cancer | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530549) |
| April 15, 2026 | NCT07530094 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable... | Ning Jiang, M.D./Ph.D. | Phase 2 | Recruiting | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 98 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530094) |
| April 9, 2026 | NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma | 250 | France, Netherlands, Puerto Rico, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519655) |
| April 9, 2026 | NCT07519486 | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC | Sichuan University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 118 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519486) |
| April 8, 2026 | NCT07518680 | A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery | Shanghai Zhongshan Hospital | Not applicable | Not yet recruiting | Esophageal Neoplasms | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518680) |
| March 19, 2026 | NCT07482566 | Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer | Nurettin Şahin | Not applicable | Recruiting | Gastroesophageal Junction Cancer, Stomach Neoplasms, Esophageal Neoplasms | 120 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07482566) |
| March 11, 2026 | NCT07464470 | Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers | Blokhin's Russian Cancer Research Center | Observational | Recruiting | Gastric Cancer, Esophageal Cancer, Brain Metastases | 30 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464470) |
| March 10, 2026 | NCT07460596 | Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Completed | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Colon and Rectal Cancer | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460596) |
| March 6, 2026 | NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Esophageal Cancer | 28 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455019) |
| March 4, 2026 | NCT07448493 | Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer | Blokhin's Russian Cancer Research Center | Observational | Active not recruiting | Gastric Cancer, Esophageal Cancer, Brain Metastases | 230 | Belarus, Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448493) |
| February 27, 2026 | NCT07440212 | Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112... | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Observational | Not yet recruiting | Esophagus Cancer | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440212) |
| February 27, 2026 | NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell... | Jiangsu Cancer Institute & Hospital | Phase 2 | Recruiting | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 22 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435454) |
| February 27, 2026 | NCT07434739 | PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies | University Hospital, Lille | Not applicable | Recruiting | Esophageal Cancer, Esophagectomy, Multimodal Analgesia, Minimally Invasive Surgery | 506 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07434739) |
| February 24, 2026 | NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric... | AstraZeneca | Phase 3 | Recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer | 2,130 | Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07431281) |
| February 18, 2026 | NCT07416825 | Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19 | Institute of Oncology Ljubljana | Not applicable | Completed | Esophageal Cancer, Esophageal Carcinoma | 23 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416825) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 12, 2026 | NCT07406815 | The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green), Lymph Node Dissection | 144 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406815) |
| February 6, 2026 | NCT07392775 | ALDH2 Genetic Testing in East Asian Community | Northwestern University | Not applicable | Not yet recruiting | Healthy Adult, Flushing | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392775) |
| February 5, 2026 | NCT07390838 | A Study of SH009 Injection in Patients With Advanced Solid Tumors. | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 1 | Recruiting | Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma... | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07390838) |
| February 3, 2026 | NCT07382635 | Clinical Trial Protocol for Evaluating the Efficacy and Safety of Thoracoabdominal Endoscopic Surgery System in Remote Laparoscopic Surgery... | Cornerstone Robotics | Observational | Not yet recruiting | Colorectal Cancer, Esophageal Cancer, Hepatectomy, Radical Hysterectomy | 98 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07382635) |
| January 29, 2026 | NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer | 73 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376876) |
| January 29, 2026 | NCT07375420 | Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer? | University of Surrey | Not applicable | Recruiting | Oesophageal Adenocarcinoma, T Cells, Tumor Microenvironment, Exercise | 50 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07375420) |
| January 27, 2026 | NCT07371247 | Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal... | The First Affiliated Hospital with Nanjing Medical University | Early phase 1 | Enrolling by invitation | Esophageal Cancer, MRD, ctDNA | 65 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371247) |
| January 26, 2026 | NCT07367516 | Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1/2 | Recruiting | Esophageal Cancer | 105 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367516) |
| January 26, 2026 | NCT07365124 | MRinRT: Swansea University and SWWCC Collaboration Study. | Swansea Bay University Health Board | Observational | Not yet recruiting | Carcinoma, Glioblastoma, Radiotherapy, MRI, MRI-guided Adaptive Radiotherapy, MRI Scanner Configuration, MRI Image... | 165 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365124) |
| January 21, 2026 | NCT07354295 | Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer （Radiogenomics-Esophagus） | Shu Peng | Observational | Recruiting | Esophageal Cancer | 1,500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354295) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| January 12, 2026 | NCT07332221 | Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial | Henan Cancer Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer | 435 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332221) |
| January 9, 2026 | NCT07330583 | Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer | AHS Cancer Control Alberta | Phase 2 | Not yet recruiting | Esophageal Cancer | 22 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330583) |
| January 7, 2026 | NCT07324018 | Spirulina Derivative for Radiation Esophagitis | West China Hospital | Phase 2 | Not yet recruiting | Radiation-induced Esophagitis | 70 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07324018) |
| January 7, 2026 | NCT07322627 | ALDH2 Single Nucleotide Polymorphisms and Prognosis of Esophageal Cancer Patients | National Taiwan University Hospital | Observational | Recruiting | Esophageal Cancer | 700 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322627) |
| December 31, 2025 | NCT07312526 | Shanghai Clinical Cohort - Esophageal Cancer | Shanghai Chest Hospital | Observational | Completed | Esophageal Cancer, Esophagectomy | 2,116 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07312526) |
| December 30, 2025 | NCT07309991 | Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy | Sun Yat-sen University | Observational | Recruiting | Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2, Esophageal Anastomotic Leakeage | 2,500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07309991) |
| December 29, 2025 | NCT07307560 | High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients | Zhejiang University | Not applicable | Recruiting | Hypoxia, Esophageal Cancer, Gastric Cancer (Diagnosis), Obstructive Sleep Apnea (OSA) | 600 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07307560) |
| December 29, 2025 | NCT07306663 | Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ... | Jiangsu Cancer Institute & Hospital | Phase 3 | Active not recruiting | Esophageal Cancer | 242 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07306663) |
| December 24, 2025 | NCT07303231 | The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | Fujian Medical University Union Hospital | Phase 3 | Not yet recruiting | Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green | 144 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07303231) |
| December 24, 2025 | NCT07301814 | Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Observational | Recruiting | Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma Cancer, Esophageal Cancer | 56 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301814) |
| December 16, 2025 | NCT07283991 | QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer | Ruijin Hospital | Phase 2 | Not yet recruiting | Esophageal Cancer | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283991) |
| December 16, 2025 | NCT07283939 | Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | Alliance for Clinical Trials in Oncology | Not applicable | Recruiting | Ampulla of Vater Carcinoma, Appendix Carcinoma, Carcinoma of Unknown Primary With Gastrointestinal Profile, Colon... | 420 | Guam, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283939) |
| December 9, 2025 | NCT07272382 | Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer | Fudan University | Not applicable | Recruiting | Esophageal Neoplasms | 142 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07272382) |
| December 3, 2025 | NCT07260734 | AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2) | Imperial College London | Observational | Not yet recruiting | OESOPHAGO-GASTRIC CARCINOMA, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction... | 6,000 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260734) |
| November 26, 2025 | NCT07251114 | AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomized Cohort Study | Fujian Provincial Hospital | Not applicable | Recruiting | Esophageal Cancer Stage, Early Esophageal Cancer | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251114) |
| November 18, 2025 | NCT07233850 | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma... | 300 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233850) |
| November 12, 2025 | NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer... | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227168) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Zhejiang University | 8 | August 28, 2026 |
| Fudan University | 8 | May 7, 2026 |
| Henan Cancer Hospital | 6 | August 21, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 6 | July 29, 2026 |
| Sichuan University | 6 | April 24, 2026 |
| Sun Yat-sen University | 4 | October 7, 2026 |
| Peking University Cancer Hospital & Institute | 4 | August 20, 2026 |
| Shanghai Zhongshan Hospital | 4 | June 5, 2026 |
| Pfizer | 3 | October 29, 2026 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 3 | October 29, 2026 |
| Ruijin Hospital | 3 | October 22, 2026 |
| Fujian Medical University Union Hospital | 3 | August 26, 2026 |
| National Taiwan University Hospital | 3 | May 22, 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 | April 15, 2026 |
| Anhui Provincial Hospital | 3 | September 23, 2025 |
| Fujian Cancer Hospital | 3 | July 1, 2025 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 | October 22, 2026 |
| Sutro Biopharma, Inc. | 2 | September 8, 2026 |
| Jazz Pharmaceuticals | 2 | August 24, 2026 |
| Imperial College London | 2 | July 20, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 65 | October 29, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 53 | October 7, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 48 | October 29, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 26 | October 29, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 13 | September 14, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 12 | October 22, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | August 24, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 1 | August 15, 2025 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | January 17, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 104 | October 29, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 46 | October 29, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 8 | April 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 8 | April 9, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 7 | September 18, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 7 | September 10, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 7 | June 4, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 7 | May 13, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 6 | May 1, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 5 | February 24, 2026 |
| [Puerto Rico](https://specstream.ai/data/clinical-trials/country/puerto-rico) | 4 | April 9, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 4 | February 24, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 4 | February 24, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 4 | February 24, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 3 | March 19, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 3 | June 15, 2025 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 2 | June 18, 2026 |
| [Russia](https://specstream.ai/data/clinical-trials/country/russia) | 2 | March 11, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 2 | February 24, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 2 | February 24, 2026 |
| [Hungary](https://specstream.ai/data/clinical-trials/country/hungary) | 2 | February 24, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 1 | July 14, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 1 | June 26, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 1 | June 11, 2026 |
| Belarus | 1 | March 4, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).